| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | Luis Brito | |
| Mansoor Amiji | |||
| P2860 | cites work | Gene therapy for vascular smooth muscle cell proliferation after arterial injury | Q45871893 |
| Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation: a gene targeting and gene transfer study in mice | Q24310475 | ||
| Clathrin-dependent endocytosis | Q24530597 | ||
| A prospective randomized antiplatelet trial of cilostazol versus clopidogrel in patients with bare metal stent | Q28195771 | ||
| How a dentist's name became a synonym for a life-saving device: the story of Dr. Charles Stent | Q28210721 | ||
| A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease | Q28238811 | ||
| Clinical experience with the Palmaz-Schatz coronary stent. Initial results of a multicenter study | Q28262174 | ||
| The pathogenesis of atherosclerosis: a perspective for the 1990s | Q29547827 | ||
| Stabilized nonviral formulations for the delivery of MCP-1 gene into cells of the vasculoendothelial system | Q31060848 | ||
| Physical characterization of controlled release of paclitaxel from the TAXUS Express2 drug-eluting stent. | Q31122959 | ||
| Deposition of nanoparticles in the arterial vessel by porous balloon catheters: localization by confocal laser scanning microscopy and transmission electron microscopy. | Q31135595 | ||
| Effects of different application parameters on penetration characteristics and arterial vessel wall integrity after local nanoparticle delivery using a porous balloon catheter | Q33203960 | ||
| In vivo phage display selection yields atherosclerotic plaque targeted peptides for imaging | Q33247563 | ||
| A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo | Q34159206 | ||
| Evidence for direct local effect of angiotensin in vascular hypertrophy. In vivo gene transfer of angiotensin converting enzyme | Q34182616 | ||
| Safety and Feasibility of Catheter-Based Local Intracoronary Vascular Endothelial Growth Factor Gene Transfer in the Prevention of Postangioplasty and In-Stent Restenosis and in the Treatment of Chronic Myocardial Ischemia | Q34196366 | ||
| Taxol inhibits neointimal smooth muscle cell accumulation after angioplasty in the rat | Q34211840 | ||
| Cell cycle in vasculoproliferative diseases: potential interventions and routes of delivery | Q34250961 | ||
| The endocytic pathway: a mosaic of domains | Q34389525 | ||
| Cell-specific targeting of nanoparticles by multivalent attachment of small molecules | Q34462201 | ||
| Endocytosis via caveolae | Q34609707 | ||
| Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene | Q34693858 | ||
| Dissecting virus entry via endocytosis | Q34697258 | ||
| Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells | Q34719651 | ||
| Gene therapy for restenosis: current status | Q34730698 | ||
| Inflammation and restenosis in the stent era. | Q34993928 | ||
| Local gene transfer of tissue factor pathway inhibitor regulates intimal hyperplasia in atherosclerotic arteries | Q35054188 | ||
| Targeting the cell cycle machinery for the treatment of cardiovascular disease. | Q35164884 | ||
| Sirolimus-eluting coronary stent. | Q35689893 | ||
| Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines | Q35749970 | ||
| Mechanisms of restenosis after coronary intervention: difference between plain old balloon angioplasty and stenting | Q73029237 | ||
| Clinical and angiographic follow-up after balloon angioplasty with provisional stenting for coronary in-stent restenosis | Q73042594 | ||
| Effect of cilostazol in preventing restenosis after percutaneous transluminal coronary angioplasty | Q73256705 | ||
| Neutrophil, not macrophage, infiltration precedes neointimal thickening in balloon-injured arteries | Q73295331 | ||
| Passivation of metallic stents after arterial gene transfer of phVEGF165 inhibits thrombus formation and intimal thickening | Q73310509 | ||
| Restenosis after coronary placement of various stent types | Q73344123 | ||
| Adenovirus-mediated transfer of a dominant-negative H-ras suppresses neointimal formation in balloon-injured arteries in vivo | Q73352792 | ||
| Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery | Q73558499 | ||
| A randomized trial of aspirin versus cilostazol therapy after successful coronary stent implantation | Q73913260 | ||
| Liposome-mediated gene transfection of endothelial nitric oxide synthase reduces endothelial activation and leukocyte infiltration in transplanted hearts | Q73966321 | ||
| In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia | Q74027568 | ||
| Ceramide-coated balloon catheters limit neointimal hyperplasia after stretch injury in carotid arteries | Q74188036 | ||
| Transfer of wild-type p53 gene effectively inhibits vascular smooth muscle cell proliferation in vitro and in vivo | Q74191229 | ||
| Morphological predictors of restenosis after coronary stenting in humans | Q74353325 | ||
| Catalytic oligodeoxynucleotides define a key regulatory role for early growth response factor-1 in the porcine model of coronary in-stent restenosis | Q74614313 | ||
| Sustained reduction of in-stent neointimal growth with the use of a novel systemic nanoparticle paclitaxel | Q74711108 | ||
| Cell cycle progression: new therapeutic target for vascular proliferative disease | Q74779512 | ||
| Targeting CCR2 or CD18 inhibits experimental in-stent restenosis in primates: inhibitory potential depends on type of injury and leukocytes targeted | Q77743548 | ||
| Gene transfer of human prostacyclin synthase prevents neointimal formation after carotid balloon injury in rats | Q77952895 | ||
| Chimeric DNA-RNA hammerhead ribozyme to proliferating cell nuclear antigen reduces stent-induced stenosis in a porcine coronary model | Q78019864 | ||
| Targeted antiproliferative drug delivery to vascular smooth muscle cells with a magnetic resonance imaging nanoparticle contrast agent: implications for rational therapy of restenosis | Q78570662 | ||
| Improved targeting of the alpha(v)beta (3) integrin by multimerisation of RGD peptides | Q80112875 | ||
| Adenovirus-mediated heme oxygenase-1 gene delivery inhibits injury-induced vascular neointima formation | Q43808895 | ||
| Overexpression of a constitutively active protein kinase G mutant reduces neointima formation and in-stent restenosis | Q43890763 | ||
| Macrophage depletion by clodronate-containing liposomes reduces neointimal formation after balloon injury in rats and rabbits | Q44082556 | ||
| Reversal of GATA-6 downregulation promotes smooth muscle differentiation and inhibits intimal hyperplasia in balloon-injured rat carotid artery | Q44130475 | ||
| Sirolimus-eluting stent for treatment of complex in-stent restenosis: the first clinical experience | Q44283408 | ||
| Efficiency of Dispatch and Infiltrator cardiac infusion catheters in arterial localization of nanoparticles in a porcine coronary model of restenosis | Q44565830 | ||
| Synergistic effects of a novel nanoporous stent coating and tacrolimus on intima proliferation in rabbits | Q44627095 | ||
| Catheter-based prostacyclin synthase gene transfer prevents in-stent restenosis in rabbit atheromatous arteries | Q44734198 | ||
| Tissue-specific expression of an anti-proliferative hybrid transgene from the human smooth muscle alpha-actin promoter suppresses smooth muscle cell proliferation and neointima formation | Q44786642 | ||
| The Dispatch catheter as a delivery tool for arterial gene transfer | Q44971545 | ||
| Extracellular matrix changes in stented human coronary arteries | Q45012599 | ||
| Novel PDGFbetaR antisense encapsulated in polymeric nanospheres for the treatment of restenosis. | Q45105336 | ||
| Tissue inhibitor of metalloproteinase 1 adenoviral gene therapy alone is equally effective in reducing restenosis as combination gene therapy in a rabbit restenosis model | Q45125597 | ||
| A novel paclitaxel-eluting porous carbon-carbon nanoparticle coated, nonpolymeric cobalt-chromium stent: evaluation in a porcine model | Q45135020 | ||
| Particle debris from a nanoporous stent coating obscures potential antiproliferative effects of tacrolimus-eluting stents in a porcine model of restenosis | Q45201729 | ||
| Extracellular superoxide dismutase with vaccinia virus anti-inflammatory protein 35K or tissue inhibitor of metalloproteinase-1: Combination gene therapy in the treatment of vein graft stenosis in rabbits | Q45417776 | ||
| Tissue factor pathway inhibitor gene delivery using HVJ-AVE liposomes markedly reduces restenosis in atherosclerotic arteries | Q45856710 | ||
| Preclinical evaluation of inducible nitric oxide synthase lipoplex gene therapy for inhibition of stent-induced vascular neointimal lesion formation | Q45859602 | ||
| Application to vascular adventitia of a nonviral vector for TIMP-1 gene therapy to prevent intimal hyperplasia | Q45861097 | ||
| Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product | Q45869776 | ||
| Optimization of nonviral gene transfer of vascular smooth muscle cells in vitro and in vivo | Q45870001 | ||
| Effect of percutaneous adenovirus-mediated Gax gene delivery to the arterial wall in double-injured atheromatous stented rabbit iliac arteries | Q45870659 | ||
| Gene therapy of transplant arteriopathy by liposome-mediated transfection of endothelial nitric oxide synthase | Q45872333 | ||
| Enhanced inhibition of neointimal hyperplasia by genetically engineered endothelial progenitor cells | Q45874341 | ||
| p27-p16 fusion gene inhibits angioplasty-induced neointimal hyperplasia and coronary artery occlusion | Q45879229 | ||
| A new cationic liposome DNA complex enhances the efficiency of arterial gene transfer in vivo | Q45879391 | ||
| Accelerated restitution of endothelial integrity and endothelium-dependent function after phVEGF165 gene transfer | Q45880294 | ||
| Local gene transduction of cyclooxygenase-1 increases blood flow in injured atherosclerotic rabbit arteries | Q45882781 | ||
| Local adenovirus-mediated transfer of human endothelial nitric oxide synthase reduces luminal narrowing after coronary angioplasty in pigs | Q45889196 | ||
| Endothelial targeting of high-affinity multivalent polymer nanocarriers directed to intercellular adhesion molecule 1. | Q46027250 | ||
| Endothelialization of microporous YIGSR/PEG-modified polyurethaneurea | Q46688940 | ||
| Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans | Q46771827 | ||
| Predictors of diffuse and aggressive intra-stent restenosis | Q46780982 | ||
| Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial | Q46782948 | ||
| Significance of elevated cytochrome aa3 in a state of endotoxemia in dogs. | Q48871196 | ||
| Summary health statistics for u.s. Adults: national health interview survey, 2004. | Q50111967 | ||
| C-type natriuretic peptide for reduction of restenosis: gene transfer is superior over single peptide administration. | Q50480205 | ||
| C-type natriuretic peptide inhibits constrictive remodeling without compromising re-endothelialization in balloon-dilated renal arteries. | Q50485260 | ||
| Application of nanoparticle technology for the prevention of restenosis after balloon injury in rats. | Q50495224 | ||
| Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. | Q51105066 | ||
| Design of a novel fibronectin-mimetic peptide-amphiphile for functionalized biomaterials. | Q51244351 | ||
| Frequency, predictors, and outcomes of drug-eluting stent utilization in patients with high-risk non-ST-segment elevation acute coronary syndromes. | Q51353466 | ||
| Drug-eluting bioabsorbable magnesium stent. | Q51580705 | ||
| Locally delivered nanoencapsulated tyrphostin (AGL-2043) reduces neointima formation in balloon-injured rat carotid and stented porcine coronary arteries. | Q51640655 | ||
| Local RAD50 gene delivery induces regression of preformed porcine coronary in-stent neointimal hyperplasia. | Q51723713 | ||
| Receptor-mediated gene delivery and expression in vivo. | Q54740305 | ||
| Differential effects of the cyclin-dependent kinase inhibitors p27(Kip1), p21(Cip1), and p16(Ink4) on vascular smooth muscle cell proliferation. | Q55033846 | ||
| Coronary-Artery Stents — Gauging, Gorging, and Gouging | Q56945059 | ||
| Percutaneous delivery of the gax gene inhibits vessel stenosis in a rabbit model of balloon angioplasty | Q57243575 | ||
| Endocytosis | Q57374715 | ||
| Peptide-Retargeted Adenovirus Encoding a Tissue Inhibitor of Metalloproteinase-1 Decreases Restenosis after Intravascular Gene Transfer | Q59704044 | ||
| VEGF Gene Transfer Reduces Intimal Thickening via Increased Production of Nitric Oxide in Carotid Arteries | Q59704277 | ||
| Local adenoviral-mediated inducible nitric oxide synthase gene transfer inhibits neointimal formation in the porcine coronary stented model | Q64377776 | ||
| Systemic tissue inhibitor of metalloproteinase-1 gene delivery reduces neointimal hyperplasia in balloon-injured rat carotid artery | Q64378343 | ||
| Intravascular adenovirus-mediated VEGF-C gene transfer reduces neointima formation in balloon-denuded rabbit aorta | Q64380325 | ||
| Expression of wild-type and noncleavable Fas ligand by tetracycline-regulated adenoviral vectors to limit intimal hyperplasia in vascular lesions | Q64380512 | ||
| P53 gene transfer to the injured rat carotid artery promotes apoptosis | Q64381169 | ||
| Human endothelial nitric oxide synthase gene transfer inhibits vascular smooth muscle cell proliferation and neointima formation after balloon injury in rats | Q64382103 | ||
| Inhibition of vascular smooth muscle cell proliferation and neointimal accumulation by adenovirus-mediated gene transfer of cytosine deaminase | Q64382357 | ||
| Local adenoviral-mediated expression of recombinant hirudin reduces neointima formation after arterial injury | Q64382923 | ||
| Nanoparticulate delivery system of a tyrphostin for the treatment of restenosis. | Q64998251 | ||
| A prescreening system for potential antiproliferative agents: implications for local treatment strategies of postangioplasty restenosis | Q70789353 | ||
| Effect of cilostazol, a novel anti-platelet drug, on restenosis after percutaneous transluminal coronary angioplasty | Q71309388 | ||
| Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study | Q71571194 | ||
| The in-vitro effect of antineoplastic agents on proliferative activity and cytoskeletal components of plaque-derived smooth-muscle cells from human coronary arteries | Q72677341 | ||
| Absorbable metal stent in human coronary arteries: imaging with intravascular ultrasound | Q35770979 | ||
| Perspective in progress of cardiovascular gene therapy | Q35778340 | ||
| In vivo suppression of injury-induced vascular smooth muscle cell accumulation using adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene | Q35871957 | ||
| Drug-eluting stents: caution and concerns for long-term outcome | Q35877832 | ||
| PDGF receptor kinase inhibitors for the treatment of restenosis | Q36017183 | ||
| Choosing a drug-eluting stent: a comparison between CYPHER and TAXUS. | Q36017745 | ||
| Molecular basis of restenosis and drug-eluting stents | Q36113806 | ||
| The efficacy of sirolimus- and paclitaxel-eluting stents: a meta-analysis of randomized controlled trials. | Q36154288 | ||
| Paclitaxel-eluting stents in coronary artery disease | Q36292672 | ||
| Site specific gene delivery in the cardiovascular system | Q36317630 | ||
| Coronary stenting and inflammation | Q36362982 | ||
| Biodegradable stents: they do their job and disappear. | Q36381899 | ||
| Inhibition of vascular smooth muscle cell proliferation and intimal hyperplasia by gene transfer of beta-interferon | Q36437774 | ||
| Restenosis following implantation of bare metal coronary stents: pathophysiology and pathways involved in the vascular response to injury | Q36491946 | ||
| Narrative review: drug-eluting stents for the management of restenosis: a critical appraisal of the evidence. | Q36511835 | ||
| Review of randomized clinical trials of drug-eluting stents for the prevention of in-stent restenosis | Q36543446 | ||
| Regulation of cellular proliferation and intimal formation following balloon injury in atherosclerotic rabbit arteries | Q37357232 | ||
| Downregulation of cyclin-dependent kinase 2 activity and cyclin A promoter activity in vascular smooth muscle cells by p27(KIP1), an inhibitor of neointima formation in the rat carotid artery | Q37367211 | ||
| Gene therapy for attenuating cardiac allograft arteriopathy using ex vivo E2F decoy transfection by HVJ-AVE-liposome method in mice and nonhuman primates | Q38306353 | ||
| Arterial uptake of biodegradable nanoparticles: effect of surface modifications | Q38549883 | ||
| PDGF-receptor tyrosine kinase blocker AG1295 selectively attenuates smooth muscle cell growth in vitro and reduces neointimal formation after balloon angioplasty in swine | Q38551733 | ||
| Sustained local drug delivery to the arterial wall via biodegradable microspheres | Q38557187 | ||
| Local delivery of biodegradable microparticles containing colchicine or a colchicine analogue: Effects on restenosis and implications for catheter-based drug delivery | Q38574692 | ||
| Adventitial versus intimal liposome-mediated ex vivo transfection of canine saphenous vein grafts with endothelial nitric oxide synthase gene | Q39553622 | ||
| Engineered polymeric nanoparticles for receptor-targeted blockage of oxidized low density lipoprotein uptake and atherogenesis in macrophages | Q40268941 | ||
| Alendronate-loaded nanoparticles deplete monocytes and attenuate restenosis. | Q40280608 | ||
| Experimental study of recombinant eukaryotic expression vector of human eNOS in ECV304. | Q40295377 | ||
| Inactivation of vascular smooth muscle cells photosensitised by liposome-delivered Zn(II)-phthalocyanine | Q40358990 | ||
| Effects of vaccinia virus anti-inflammatory protein 35K and TIMP-1 gene transfers on vein graft stenosis in rabbits | Q40426469 | ||
| Systemic depletion of macrophages by liposomal bisphosphonates reduces neointimal formation following balloon-injury in the rat carotid artery. | Q40623402 | ||
| Selective augmentation of prostacyclin production by combined prostacyclin synthase and cyclooxygenase-1 gene transfer | Q40810428 | ||
| Prostacyclin and nitric oxide-related gene transfer in preventing arterial thrombosis and restenosis. | Q41492602 | ||
| The molecular bases of restenosis | Q41609815 | ||
| Nitric oxide (NO) donor molecules: effect of NO release rate on vascular smooth muscle cell proliferation in vitro | Q42276791 | ||
| Ca2+, calmodulin, and cyclins in vascular smooth muscle cell cycle | Q42416262 | ||
| Overexpression of human endothelial nitric oxide synthase in rat vascular smooth muscle cells and in balloon-injured carotid artery | Q42454758 | ||
| Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease | Q43571686 | ||
| Lipoplex gene transfer of inducible nitric oxide synthase inhibits the reactive intimal hyperplasia after expanded polytetrafluoroethylene bypass grafting | Q43597747 | ||
| Efficient inhibition of intimal hyperplasia by adenovirus-mediated inducible nitric oxide synthase gene transfer to rats and pigs in vivo | Q43610465 | ||
| Formulation and delivery mode affect disposition and activity of tyrphostin-loaded nanoparticles in the rat carotid model | Q43738075 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | nanoparticle | Q61231 |
| gene therapy | Q213901 | ||
| nanomedicine | Q261659 | ||
| anti-inflammatory agent | Q581996 | ||
| manufactured product | Q3406743 | ||
| drug carrier | Q3715494 | ||
| coronary restenosis | Q18556246 | ||
| pharmaceutical preparation | Q66089252 | ||
| biomedical investigative technique | Q66648976 | ||
| P304 | page(s) | 143-61 | |
| P577 | publication date | 2007-01-01 | |
| P1433 | published in | International Journal of Nanomedicine | Q6051502 |
| P1476 | title | Nanoparticulate carriers for the treatment of coronary restenosis | |
| P478 | volume | 2 |
| Q38067933 | Advances in nanotechnology for the management of coronary artery disease |
| Q55516366 | Application of Light Scattering Techniques to Nanoparticle Characterization and Development. |
| Q28476506 | Effects of an alpha-4 integrin inhibitor on restenosis in a new porcine model combining endothelial denudation and stent placement |
| Q30475719 | Emerging applications of nanomedicine for the diagnosis and treatment of cardiovascular diseases |
| Q39982286 | Enhancement in anti-proliferative effects of paclitaxel in aortic smooth muscle cells upon co-administration with ceramide using biodegradable polymeric nanoparticles |
| Q35979148 | Formulation, antileukemia mechanism, pharmacokinetics, and biodistribution of a novel liposomal emodin |
| Q30447539 | Gold nanoparticles: From nanomedicine to nanosensing. |
| Q34419883 | In situ re-endothelialization via multifunctional nanoscaffolds |
| Q35585791 | In vivo prevention of arterial restenosis with paclitaxel-encapsulated targeted lipid-polymeric nanoparticles |
| Q35802696 | Inhibition of intimal hyperplasia via local delivery of vascular endothelial growth factor cDNA nanoparticles in a rabbit model of restenosis induced by abdominal aorta balloon injury |
| Q36344315 | Microfabrication and nanotechnology in stent design |
| Q39276023 | Nanomedicine in coronary artery disease |
| Q58610559 | Nanoparticle Eluting-Angioplasty Balloons to Treat Cardiovascular Diseases |
| Q37947952 | Nanoparticle-based drug delivery: case studies for cancer and cardiovascular applications. |
| Q30362371 | Nanotechnology in diagnosis and treatment of coronary artery disease. |
| Q59793745 | Nanotechnology, an alternative with promising prospects and advantages for the treatment of cardiovascular diseases |
| Q37944416 | Restenosis after PCI. Part 2: prevention and therapy |
| Q41383344 | [Pyr1]-Apelin-13 delivery via nano-liposomal encapsulation attenuates pressure overload-induced cardiac dysfunction. |
Search more.